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Abstract
Many research-funding agencies now require open access to the results of research they have
funded, and some also require that researchers make available the raw data generated from that
research. Similarly, the journal Trials aims to address inadequate reporting in randomised controlled
trials, and in order to fulfil this objective, the journal is working with the scientific and publishing
communities to try to establish best practice for publishing raw data from clinical trials in peer-
reviewed biomedical journals. Common issues encountered when considering raw data for
publication include patient privacy – unless explicit consent for publication is obtained – and
ownership, but agreed-upon policies for tackling these concerns do not appear to be addressed in
the guidance or mandates currently established. Potential next steps for journal editors and
publishers, ethics committees, research-funding agencies, and researchers are proposed, and
alternatives to journal publication, such as restricted access repositories, are outlined.
Introduction
Assessment of the reliability of published articles is seri-
ously impeded by incomplete reporting [1]. But even if a
study is impeccably reported, we usually have access only
to summary information from a limited number of anal-
yses. The availability of individual patient data, 'raw data',
to the scientific community would allow many other anal-
yses and realise a variety of benefits for science and, as a
consequence, patient care. Indeed, recommendations for
sharing data resulting from publicly funded research have
become more common in the past few years. These
include requirements of the National Institutes of Health
[2], the Medical Research Council [3], and the Wellcome
Trust [4]. Advocates of scientific data sharing such as the
Science Commons network also strongly support this
position:
'Research data, data sets, databases, and protocols should be in
the public domain. This status ensures the ability to freely dis-
tribute, copy, re-format, and integrate data from research into
new research, ensuring that as new technologies are developed
researchers can apply those technologies without legal barriers.
Scientific traditions of citation, attribution, and acknowledg-
ment should be cultivated in norms' [5].
An article published in a meteorological journal describes
data publication as an 'implicit part of the scientific
method' [6], but very few clinical trialists currently make
their raw data available. There are few strong incentives or
requirements for doing so, nor is there a culture of data
sharing, as has been established in other disciplines, such
as the microarray [7] research community. Yet the benefits
of sharing raw data have been recognised for many years.
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Sir Francis Galton wrote in 1901: 'I have begun to think
that no one ought to publish biometric results, without
lodging a well-arranged and well-bound manuscript copy
of his data in some place where it should be accessible,
under reasonable restrictions, to those who desire to verify
his work' [8].
Sufficiently preserved and replicable data are more abso-
lute than contemporaneously drawn conclusions and, if
they are collected to address one scientific question, can
later be applied for the solution of entirely different prob-
lems [9]. A key objective of this journal is to complete the
scientific record by encouraging the publication of the
enormous amounts of data collected over the course of
randomised controlled trials [10].
The benefits of sharing clinical trial data are well docu-
mented and include reproducing and checking analyses,
secondary-hypothesis testing, comparisons with previous
studies, simplifying and enhancing subsequent systematic
reviews and meta-analyses, and teaching [11,12]. This
level of transparency also increases an article's contribu-
tion to methodological aspects of research and provides
opportunities for increasing the sophistication of analyses
[13]. It has further been suggested that the risk of fraud in
drug trials will be reduced, as adverse events may be iden-
tified sooner [14]. And for those concerned with Impact
Factors, making raw data available has also been sug-
gested to be associated with an increased citation rate
[15]. Conversely, however, the Health Canada Working
Group on the Registration and Disclosure of Clinical Trial
Information deemed access to raw data unnecessary,
describing raw data as poorly defined and noting poten-
tial problems with consent for release of the data [16].
By providing unrestricted space, online journals such as
Trials take the notion of sharing research data a stage fur-
ther by giving authors the opportunity to publish raw
data, alongside the main trial report, as supplementary
material. In this editorial, we will discuss some of the
challenges and opportunities for publishing raw trial data
in peer-reviewed journals and propose some possible
ways forward for different members of the research com-
munity.
What guidance is available?
Because researchers have not been publishing or openly
sharing raw clinical trial data in biomedical journals to
any great extent, the ethical and legal issues surrounding
how it should be done in an appropriate and informed
way have not been thoroughly worked out. In 2001,
Gunther Eysenbach, the editor of the Journal of Medical
Internet Research, and Eun-Ryoung Sa [17] called for a
code of conduct for publishing raw data, and in an article
in this journal, a code was subsequently proposed for tri-
alists and independent investigators wishing to re-analyse
raw data [11]. But a widely transferable publication policy
that could be adopted by many groups – authors, editors,
publishers, funding agencies, ethics committees, and
institutions – does not appear to have emerged.
Journal policies
In several journals, including Trials, the instructions for
authors include a requirement for submitting authors to
be prepared to share their raw data with other scientists on
request. Some journals have begun requiring access to raw
data as a condition of publication, or at least transparency
with regard to its availability [18,19]. The Annals of Inter-
nal Medicine's 'reproducible research' initiative,
announced in 2007 to increase confidence in the scientific
record, set out the minimum requirements for data shar-
ing to ensure that independent investigators could repro-
duce published research if they desired: 'the original
protocol, the dataset used for the analysis, and the compu-
ter code used to produce the results' [19]. Annals  asks
authors to specify the extent to which they will share their
data and any conditions for sharing.
Journal policies have been associated with the increased
prevalence of sharing of certain types of research data, but
the overall prevalence of clinical data sharing remains low
[20]. And in high-throughput research and publishing
environments, policing policy adherence may be beyond
the resources of even the largest organisations. The growth
of online open-access publishing, often without restric-
tions on supplementary material, should, in principle,
provide the platform for publishing raw data. But several
issues commonly arise as barriers to publishing raw data
in journals.
Confidentiality and anonymity
A key concern for any use of personal health information
must be anonymity [21]. Publishing data that have arisen
from the doctor-patient relationship whilst preserving the
privacy of individuals – unless explicit consent has been
obtained – remains a challenge, particularly in light of
statutes such as the Health Insurance Portability and
Accountability Act (HIPAA) in the US and the Data Pro-
tection Act in the UK. For example, the confidentiality
policy of the BMJ, a UK-based publication, has been estab-
lished to comply with the Data Protection Act [22]. How-
ever, in an increasingly global publishing industry,
universally agreed-upon definitions as to what constitutes
anonymised (or 'de-identified') information arising from
personal health records do not appear to have been estab-
lished.
Publishing and editorial support groups' privacy policies
are reasonably clear with regard to individual patient case
histories and small case series [23,24], but for larger clin-Trials 2009, 10:17 http://www.trialsjournal.com/content/10/1/17
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ical studies, in which the raw data can still contain
detailed information about individuals, there seems to be
a lack of appropriate guidance on how a researcher would
tackle this issue. If a data set can be anonymised so that
neither the patient nor anyone else could identify an indi-
vidual, then data are no longer 'personal', negating the
issue of consent for publication. The benefits of access to
the full data set for the scientific community could argua-
bly outweigh the small risk that an individual within a
data set might be identified. Complete anonymity can be
difficult to achieve with certainty, as noted by the Interna-
tional Committee of Medical Journal Editors [24]. But for
the majority of clinical trial data sets, confidentiality
would rarely be a concern if the data consisted of very
common baseline demographic information and one
additional variable (such as pain scores in a trial of treat-
ment for pain). The HIPAA provides an explicit list of 18
items that need to be removed from patient information
in order for it to be considered anonymous for sharing
(rather than publishing) information among the Act's
'covered entities' [25].
Ownership
Ownership of raw data sets is also a contentious issue.
Although trialists may in some cases be the legal owners
of their data sets, whether it is morally right for researchers
to keep potentially useful information arising from per-
sonal health records is debatable [11]. Moreover, where
data have been generated via a collaborative effort by mul-
tiple researchers (often during the course of employ-
ment), potential infringements of third-party rights may
also need to be considered. However, as noted in the
Research Information Network's study, published in June
2008, researchers themselves are often unsure of who
owns their data [26]. With regard to publishing data, the
Association of Learned and Professional Society Publish-
ers issued a statement in 2006, supporting sharing of raw
data sets among scholars as a general principle [27]. It rec-
ommends that publishers separate supporting data from
the article itself and not require transfer of copyright as a
condition of publication.
Other challenges and opportunities
Medical journals must often subscribe to more stringent
publication policies for peer-reviewed articles compared
with other means of disseminating information, such as
the lay press, so it is reasonable to assume that the same
should apply for raw data sets. Publishing raw data from
'historic' trials is particularly problematic as it is unlikely
that allowances for such reuse of the data will have been
made in patient consent forms for trials conducted many
years ago. And this may still be the case for newly
approved trials. Where explicit consent for publication of
data is not obtainable, approval for release of data is desir-
able, but from which person or organisation is generally
unclear.
This is highlighted by the limited access to data sets of the
US National Heart Lung and Blood Institute (NHLBI)
when there is an absence of clear approval by study
patients for data sharing in older studies. The NHLBI insti-
tutional review board requires that there be agreement by
data recipients that they will not try to identify any indi-
viduals and that an institution will vouch for the integrity
of the process. If consent to release data is obtained from
patients, this extra step is not needed [28,29]. The practice
of obtaining consent retrospectively presents its own
problems. The value of a data set is diminished if one or
more patients decline consent or cannot be traced, and
the requirement to obtain retrospective consent also lacks
a consensus. However, some ethical guidelines on the
management of clinical trial data can require informed
consent from the patient for any reuse, redistribution, or
publication of the data from the trial [30].
Possible ways forward
In light of all of these considerations, it seems a policy that
could be followed by many groups, including editors, the
industry, ethics committees, and research-funding agen-
cies, would be an important step forward. It has been rec-
ommended that academic institutions take the lead on
data-sharing initiatives by providing incentives, funds,
and publication policies [31], but we would argue that
there are roles for a number of parties who are affected by
data sharing and publication.
In September 2008, the editors of this journal convened a
meeting with relevant members of the scientific and pub-
lishing communities to discuss these issues. Whether the
data being published are from previously published trials
or from proposed or ongoing research emerged as a key
consideration. Publication of data from historic trials is
likely to need a case-by-case assessment taking into
account any special circumstances surrounding a trial, and
who is best placed to give this advice or approval remains
open to debate. Nevertheless, some suggestions for other
members of the community likely to be involved in pro-
spective data publication are outlined below.
Ethics committees: Encourage researchers to include plans
to publish data in trial information sheets and discuss the
safeguards in place to protect patient privacy.
Research-funding agencies: Give greater scrutiny to data-
sharing plans and monitor their enforcement.
Journal editors and publishers: Recommend that authors
prepare data in line with an agreed-upon standard (what
this is requires further consideration). Encourage deposi-Trials 2009, 10:17 http://www.trialsjournal.com/content/10/1/17
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tion of data in the journal or suitable third-party reposi-
tory as part of the submission process, potentially via an
accession number system, as is established for trial regis-
tration.
Trialists: Obtain explicit consent for publication of suita-
bly anonymised raw data as part of patient recruitment
procedures.
Sharing data without publication
Different publication standards might be required for
individual studies (for example, those involving sensitive
or rare conditions) or studies involving certain popula-
tions. There are circumstances in which all the raw data
cannot be in the public domain and these different stand-
ards could incorporate differing levels of access to certain
types of data and/or embargoes on access. And where
publication of trial data in journals is not possible, the
involvement of a suitable third party could be considered,
with appropriate restrictions on access where necessary.
Accreditation schemes for researchers wishing to access
data, as instigated at the NHLBI, would be a logical part of
this process.
Online repositories for data sets, such as the Dataverse
Network Project [32], do exist, and the number of institu-
tional repositories has increased markedly since 2002
[33]. In the social sciences in particular, a number of data
archives have been established [34]. But regardless of
what restrictions on access are in place, a researcher wish-
ing, for example, to find all currently available data sets
from trials of a particular drug in a particular condition
would face significant challenges given the poor support
for sharing clinical data and lack of consensus on the
appropriate repository.
Concluding remarks
Can we agree on best practice for publishing raw clinical
trial data? An important step forward will be to prepare
widely agreeable guidance on preparing raw data for pub-
lication and recommendations for researchers on han-
dling retrospective and prospective trial data: a challenge
the editors of this journal are currently undertaking. How-
ever, mandates will need to be established at the funder,
institution, or journal level to facilitate and influence cul-
tural changes. The US Food and Drug Administration
(FDA) Amendments Act of 2007, for example, now
requires disclosure of trial results  supporting FDA-
approved drugs within a year of drug approval [35]. Once
there is increased prevalence of data sharing and publica-
tion in the clinical trials community, the further chal-
lenges (not specifically addressed in this article) of how
data sharing is to be standardised and what in fact consti-
tutes 'the raw data set' can subsequently be tackled.
Postscript
Any members of the clinical trials community interested
in participating in this journal's initiative to agree on best
practice for publishing raw clinical data are encouraged to
contact the editorial office at editorial@trialsjournal.com.
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